Skip to content

Rational Design of Exercise Tolerance Improvement Trial: A 12 weeks, Randomized, Multicenter study of TanYu Tongzhi Capsule in Stable Coronary Artery Disease (ETITYS)

Rational Design of Exercise Tolerance Improvement Trial: A 12 weeks, Randomized, Multicenter Study of TanYu Tongzhi Capsule in Stable Coronary Artery Disease (ETITYS)

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17012938
Enrollment
Unknown
Registered
2017-10-11
Start date
2017-10-20
Completion date
Unknown
Last updated
2018-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stable Coronary Artery Disease(SCAD)

Interventions

the treatment group:optimal medical therapy and Tanyu Tongzhi capsule
the control group:optimal medical therapy

Sponsors

The First Affiliated Hospital of Zhejiang Chinese Medical University(Zhejiang Provincal Hospital of TCM)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. aged 18 = years; 2. Diagnosis of stable coronary artery disease 3 months before enrollment; 3. Coronary artery disease documented by at least one of the followings: history of myocardial infarction, coronary angioplasty, bypass, coronary angiography with at least 50% stenosis in one of the major coronary arteries, positive stress echocardiography showing regional wall motion abnormalities or no improvement in left ventricular ejection fraction under exercise; 4. Normal ST-segment with sinus rhythm in a 12-lead ECG at rest, and no bundle branch block; 5. Willing to participate by signing the informed consent document.

Exclusion criteria

Exclusion criteria: 1. Acute coronary syndrome within the past 3 months; 2. Left ventricular ejection fractionupper limit of normal or albumin <the lower limit of normal; 5. Creatinine clearance <40ml/min/1.73m2 as estimated by the Cockcroft-Gault equation; 6. Combined with the endocrine system, hematopoietic system, cancer, psychosis and other severe primary diseases; 7. Preparing for pregnancy within 3 months, pregnant, breasting feeding women; 8. Allergic to the study drugs or their ingredients; 9. Unable to complete the exercise test; 10. Life expectancy of < 1 year; 11. Researchers estimate that the patient cannot complete or comply with this study.

Design outcomes

Primary

MeasureTime frame
The change of Total exercise duration after 12 weeks treatment;serum lipid levels;medication side effects;

Secondary

MeasureTime frame
The change of the time to onset of angina;The time to 1 mm ST segment depression;Seattle standard Questionnaire(SAQ);Adverse events;hs-CRP;TCMSSS;TCMSSS;

Countries

China

Contacts

Public ContactWei Mao

The First Affiliated Hospital of Zhejiang Chinese Medical University(Zhejiang Provincal Hospital of TCM)

maoweilw@163.com+86 13857125008

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026